Constellation Pharmaceuticals Readies $80 Million IPO Plans via Seeking Alpha

"Constellation is currently working on two lead products, the CPI-1205, an EZH2 inhibitor, and CPI-0610, a BET inhibitor.....The CPI-0610 is a selective small molecule which promotes anti-tumor activity by inhibiting the function of BET proteins, which normally enhances target gene expression. The company is currently enrolling patients in an open-label Phase 2 clinical trial........Assuming a successful IPO, the company’s post-IPO market capitalization would be approximately $406 million, excluding the effects of underwriter over-allotment options."